Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation initiation factor 3 subunit I pseudogene 1 (EIF3IP1) is a human pseudogene, which means it shares high sequence similarity with a functional gene (EIF3I) but encodes a non-functional, non-protein-coding transcript due to acquired mutations. Pseudogenes can sometimes give rise to non-coding RNAs that have regulatory functions, such as the production of small interfering RNAs (siRNAs) or acting as competitive endogenous RNAs (ceRNAs), thereby modulating gene expression indirectly. However, there is no evidence that EIF3IP1 serves as a conventional drug target, nor is it associated with direct disease mechanisms or used in clinical biomarker panels. EIF3IP1 is thus best classified as a pseudogene with potential, but not established, regulatory RNA functions, not as a canonical molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 3 subunit I pseudogene 1 (EIF3IP1).